Audited Financial Results for the quarter and year ended March 31, 2026
JUBLPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Jubilant Pharmova reported consolidated revenue of ₹22,900 million for Q4 FY26, up 18.7% YoY from ₹19,288 million in Q4 FY25. Full year FY26 revenue grew 13.6% to ₹82,796 million from ₹72,913 million. However, profit after tax (PAT) declined marginally to ₹5,393 million in FY26 from ₹5,458 million in FY25 (down 1.2%). The company reported exceptional items including a ₹236 million gain on sale of held-for-sale assets at its US facility and ₹535 million in expenses due to temporary suspension of manufacturing at its Montreal facility for remediation of regulatory observations. EBITDA margin compressed from 12.9% in FY25 to 11.6% in FY26. The Board recommended a final dividend of 500% (₹5 per share) for FY26.
Revenue growth demonstrates business momentum, but PAT decline and EBITDA margin compression indicate operational challenges from the Montreal facility suspension. The dividend payout signals management confidence despite near-term headwinds.